Carboxamide SIRT1 inhibitors block DBC1 binding via an acetylation- independent mechanism

Cell Cycle

Volumn 12, Issue 14, 2013, Pages 2233-2240

  Hubbard, Basil P ^a,d   Loh, Christine ^b   Gomes, Ana P ^a   Li, Jun ^a   Lu, Quinn ^b   Doyle, Taylor L G ^b   Disch, Jeremy S ^b   Armour, Sean M ^a,e   Ellis, James L ^b   Vlasuk, George P ^b   Sinclair, David A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DBC1; DBC1 acetylation; DBC1 localization; SIRT1 inhibitors; SIRT1 DBC1 complex regulation

Indexed keywords

DELETED BREAST CANCER 1; EX 527; SELISISTAT; SIRTUIN 1; SMALL MOLECULE TRANSPORT AGENT; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

EID: 84880444482     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25268     Document Type: Article

References (56)

1. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429:771-6; PMID:15175761; http://dx.doi.org/10.1038/nature02583 (Pubitemid 38833129)
2. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008; 14:661-73; PMID:18477450; http://dx.doi.org/10.1016/j.devcel.2008.02.004 (Pubitemid 351622608)
3. Biason-Lauber A, Böni-Schnetzler M, Hubbard BP, Bouzakri K, Brunner A, Cavelti-Weder C, et al. Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab 2013; 17:448-55; PMID:23473037; http://dx.doi.org/ 10.1016/j.cmet.2013.02.001
4. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007; 6:759-67; PMID:17877786; http://dx.doi.org/10.1111/j.1474-9726.2007. 00335.x (Pubitemid 350131044)
5. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339:1216-9; PMID:23471411; http://dx.doi.org/10.1126/science.1231097
6. Imai S, Kiess W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci 2009; 14:2983-95; PMID:19273250; http://dx.doi.org/10.2741/3428
7. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450:712-6; PMID:18046409; http://dx.doi.org/10.1038/ nature06261 (Pubitemid 350207685)
8. Han J, Hubbard BP, Lee J, Montagna C, Lee HW, Sinclair DA, et al. Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene. Cell Cycle 2013; 12:263-70; PMID:23255128; http://dx.doi.org/10.4161/cc.23056
9. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3:e2020; PMID:18414679; http://dx.doi.org/10.1371/ journal.pone.0002020
10. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26:3169-79; PMID:17581637; http://dx.doi.org/10.1038/sj.emboj.7601758 (Pubitemid 47057498)
11. Sauve AA. Pharmaceutical strategies for activating sirtuins. Curr Pharm Des 2009; 15:45-56; PMID:19149602; http://dx.doi.org/10.2174/138161209787185797
12. Bitterman KJ, Anderson RM, Cohen HY, Latorre- Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002; 277:45099-107; PMID:12297502; http://dx.doi.org/10.1074/jbc.M205670200 (Pubitemid 36159111)
13. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007; 9:1253-62; PMID:17934453; http://dx.doi.org/10.1038/ncb1645 (Pubitemid 350042357)
14. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, Stukenberg PT, et al. Phosphorylation regulates SIRT1 function. PLoS One 2008; 3:e4020; PMID:19107194; http://dx.doi.org/10.1371/journal.pone.0004020
15. Kang H, Jung JW, Kim MK, Chung JH. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 2009; 4:e6611; PMID:19680552; http://dx.doi.org/10.1371/ journal.pone.0006611
16. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28:277-90; PMID:17964266; http://dx.doi.org/10.1016/j.molcel.2007.08.030
17. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008; 451:587-90; PMID:18235502; http://dx.doi.org/10.1038/nature06515 (Pubitemid 351186268)
18. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008; 451:583-6; PMID:18235501; http://dx.doi.org/10.1038/nature06500 (Pubitemid 351186264)
19. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 2002; 99:13647-52; PMID:12370419; http://dx.doi.org/10. 1073/pnas.212516099 (Pubitemid 35215435)
20. Sundararajan R, Chen G, Mukherjee C, White E. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene 2005; 24:4908-20; PMID:15824730; http://dx.doi.org/10.1038/sj.onc.1208681 (Pubitemid 41129095)
21. Trauernicht AM, Kim SJ, Kim NH, Boyer TG. Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol 2007; 21:1526-36; PMID:17473282; http://dx.doi.org/10.1210/me.2007-0064 (Pubitemid 47001079)
22. Trauernicht AM, Kim SJ, Kim NH, Clarke R, Boyer TG. DBC-1 mediates endocrine resistant breast cancer cell survival. Cell Cycle 2010; 9:1218-9; PMID:20237431; http://dx.doi.org/10.4161/cc.9.6.11010
23. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA 2012; 109:E187-96; PMID:22190494; http://dx.doi.org/10.1073/pnas.1105304109
24. Chini CC, Escande C, Nin V, Chini EN. HDAC3 is negatively regulated by the nuclear protein DBC1. J Biol Chem 2010; 285:40830-7; PMID:21030595; http://dx.doi.org/10.1074/jbc.M110.153270
25. Li Z, Chen L, Kabra N, Wang C, Fang J, Chen J. Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 2009; 284:10361-6; PMID:19218236; http://dx.doi.org/10.1074/jbc. M900956200
26. Chini CC, Escande C, Nin V, Chini EN. DBC1 (Deleted in Breast Cancer 1) modulates the stability and function of the nuclear receptor Rev-erbα. Biochem J 2013; 451:453-61; PMID:23398316; http://dx.doi.org/10.1042/BJ20121085
27. Close P, East P, Dirac-Svejstrup AB, Hartmann H, Heron M, Maslen S, et al. DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. Nature 2012; 484:386-9; PMID:22446626; http://dx.doi.org/10.1038/nature10925
28. Kang H, Suh JY, Jung YS, Jung JW, Kim MK, Chung JH. Peptide switch is essential for Sirt1 deacetylase activity. Mol Cell 2011; 44:203-13; PMID:22017869; http://dx.doi.org/10.1016/j.molcel.2011.07.038
29. Raynes R, Pombier KM, Nguyen K, Brunquell J, Mendez JE, Westerheide SD. The SIRT1 modulators AROS and DBC1 regulate HSF1 activity and the heat shock response. PLoS One 2013; 8:e54364; PMID:23349863; http://dx.doi.org/10.1371/ journal. pone.0054364
30. Escande C, Chini CC, Nin V, Dykhouse KM, Novak CM, Levine J, et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 2010; 120:545-58; PMID:20071779; http://dx.doi.org/10.1172/JCI39319
31. Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, et al. Brown remodeling of white adipose tissue by SirT1- dependent deacetylation of Pparγ. Cell 2012; 150:620-32; PMID:22863012; http://dx.doi.org/10.1016/j.cell.2012.06.027
32. Kim JE, Lou Z, Chen J. Interactions between DBC1 and SIRT 1 are deregulated in breast cancer cells. Cell Cycle 2009; 8:3784-5; PMID:19855164; http://dx.doi.org/10.4161/cc.8.22.10055
33. Nin V, Escande C, Chini CC, Giri S, Camacho-Pereira J, Matalonga J, et al. Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem 2012; 287:23489-501; PMID:22553202; http://dx.doi.org/10.1074/jbc. M112.365874
34. Yuan J, Luo K, Liu T, Lou Z. Regulation of SIRT1 activity by genotoxic stress. Genes Dev 2012; 26:791-6; PMID:22465953; http://dx.doi.org/10.1101/gad. 188482.112
35. Donmez G, Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010; 9:285-90; PMID:20409078; http://dx.doi.org/10.1111/j.1474-9726.2010. 00548.x
36. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006; 26:28-38; PMID:16354677; http://dx.doi.org/10.1128/MCB.26.1.28-38.2006
37. Disch JS, Evindar G, Chiu CH, Blum CA, Dai H, Jin L, et al. Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3. J Med Chem 2013; 56:3666-79; PMID:23570514; http://dx.doi.org/10.1021/ jm400204k
38. Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat Struct Biol 2001; 8:621-5; PMID:11427894; http://dx.doi.org/10.1038/89668 (Pubitemid 32613012)
39. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005; 17:855-68; PMID:15780941; http://dx.doi.org/10.1016/j.molcel.2005.02. 022 (Pubitemid 40386946)
40. Cosgrove MS, Bever K, Avalos JL, Muhammad S, Zhang X, Wolberger C. The structural basis of sirtuin substrate affinity. Biochemistry 2006; 45:7511-21; PMID:16768447; http://dx.doi.org/10.1021/bi0526332 (Pubitemid 43894945)
41. Blum CA, Ellis JL, Loh C, Ng PY, Perni RB, Stein RL. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 2011; 54:417-32; PMID:21080630; http://dx.doi.org/10.1021/jm100861p
42. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005; 3:e41; PMID:15719057; http://dx.doi.org/10.1371/journal. pbio.0030041
43. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48:8045-54; PMID:16335928; http://dx.doi.org/10.1021/ jm050522v (Pubitemid 41798434)
44. Medda F, Russell RJ, Higgins M, McCarthy AR, Campbell J, Slawin AM, et al. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem 2009; 52:2673-82; PMID:19419202; http://dx.doi.org/10.1021/jm8014298
45. Pirrie L, McCarthy AR, Major LL, Morkunaite V, Zubriene A, Matulis D, et al. Discovery and validation of SIRT2 inhibitors based on tenovin-6: use of a 1H-NMR method to assess deacetylase activity. Molecules 2012; 17:12206-24; PMID:23079492; http://dx.doi.org/10.3390/molecules171012206
46. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369-80; PMID:15152190; http://dx.doi.org/10.1038/ sj.emboj.7600244 (Pubitemid 38954844)
47. Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci USA 2004; 101:12288-93; PMID:15284440; http://dx.doi.org/10.1073/pnas. 0404041101 (Pubitemid 39145436)
48. Remy I, Michnick SW. A highly sensitive proteinprotein interaction assay based on Gaussia luciferase. Nat Methods 2006; 3:977-9; PMID:17099704; http://dx.doi.org/10.1038/nmeth979 (Pubitemid 44782695)
49. Toki T, Katsuoka F, Kanezaki R, Xu G, Kurotaki H, Sun J, et al. Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment. Blood 2005; 105:3100-8; PMID:15613547; http://dx.doi.org/10.1182/ blood-2004-07-2826
50. Stokes MP, Rush J, Macneill J, Ren JM, Sprott K, Nardone J, et al. Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci USA 2007; 104:19855-60; PMID:18077418; http://dx.doi.org/10.1073/pnas.0707579104
51. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA 2004; 101:12130-5; PMID:15302935; http://dx.doi.org/10. 1073/pnas.0404720101 (Pubitemid 39145408)
52. Zhao X, Allison D, Condon B, Zhang F, Gheyi T, Zhang A, et al. The 2.5 Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J Med Chem 2013; 56:963-9; PMID:23311358; http://dx.doi.org/10.1021/jm301431y
53. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 2010; 1804:1626-34; PMID:19897059; http://dx.doi.org/10.1016/j.bbapap.2009.10. 025
54. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-6; PMID:12939617; http://dx.doi.org/10.1038/nature01960 (Pubitemid 37150899)
55. Sauve AA, Moir RD, Schramm VL, Willis IM. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 2005; 17:595-601; PMID:15721262; http://dx.doi.org/10.1016/j.molcel.2004.12.032 (Pubitemid 40269123)
56. Yang Y, Hubbard BP, Sinclair DA, Tong Q. Characterization of murine SIRT3 transcript variants and corresponding protein products. J Cell Biochem 2010; 111:1051-8; PMID:20677216; http://dx.doi.org/10.1002/jcb.22795